Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer

International Journal of Cancer

Volumn 126, Issue 12, 2010, Pages 2762-2772

  Delage, Barbara ^a   Fennell, Dean A ^b   Nicholson, Linda ^c   McNeish, Iain ^a,d   Lemoine, Nicholas R ^a,d   Crook, Tim ^e   Szlosarek, Peter W ^a,d  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Apoptosis; Arginase; Arginine; Arginine deiminase; Argininosuccinate synthetase; Auxotrophy; Cancer; Methylation; Platinum

Indexed keywords

AGMATINE; ARGININE; ARGININE DEIMINASE; ARGININOSUCCINATE SYNTHASE; GLUTAMIC ACID; NITRIC OXIDE; PLATINUM; POLYAMINE DERIVATIVE; PROLINE;

APOPTOSIS; AUXOTROPHY; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER THERAPY; CARCINOGENESIS; COLORECTAL CANCER; ENZYME DEGRADATION; ENZYME REGULATION; HUMAN; INFLAMMATION; INFLAMMATORY CELL; KIDNEY CANCER; LIVER CELL CARCINOMA; MELANOMA; NONHUMAN; OVARY CANCER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; STOMACH CANCER; ANIMAL; ENZYMOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; PROGNOSIS;

ANIMALS; ARGININE; ARGININOSUCCINATE SYNTHASE; HUMANS; NEOPLASMS; PROGNOSIS;

EID: 77951903067     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25202     Document Type: Review

References (86)

1. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008;13:472-482
2. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008;18:54-61.
3. Pan JG, Mak TW. Metabolic targeting as an anticancer strategy: dawn of a new era? Sci STKE 2007;2007:pe14.
4. Wu G, Morris SM, Jr. Arginine metabolism: nitric oxide and beyond. Biochem J 1998;336 (Pt 1):1-17.
5. Yerushalmi HF, Besselsen DG, Ignatenko NA, Blohm-Mangone KA, Padilla-Torres JL, Stringer DE, Guillen JM, Holubec H, Payne CM, Gerner EW. Role of polyamines in arginine-dependent colon carcinogenesis in Apc(Min) (/+) mice. Mol Carcinog 2006;45:764-773
6. Yerushalmi HF, Besselsen DG, Ignatenko NA, Blohm-Mangone KA, Padilla-Torres JL, Stringer DE, Cui H, Holubec H, Payne CM, Gerner EW. The role of NO synthases in arginine-dependent small intestinal and colonic carcinogenesis. Mol Carcinog 2006; 45:93-105. (Pubitemid 43202582)
7. Gilroy E. The influence of arginine upon the growth rate of a transplantable tumour in the mouse. Biochem J 1930;24:589-595
8. Yeatman TJ, Risley GL, Brunson ME. Depletion of dietary arginine inhibits growth of metastatic tumor. Arch Surg 1991;126:1376-81; discussion 81-82
9. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006;6:521-534 (Pubitemid 43980541)
10. Ekmekcioglu S, Ellerhorst JA, Prieto VG, Johnson MM, Broemeling LD, Grimm EA. Tumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer 2006;119:861-866 (Pubitemid 44051450)
11. Yamamoto T, Terada N, Seiyama A, Nishizawa Y, Akedo H, Kosaka H. Increase in experimental pulmonary metastasis in mice by L-arginine under inhibition of nitric oxide production by NG-nitro-L-arginine methyl ester. Int J Cancer 1998;75: 140-144 (Pubitemid 28113989)
12. Ma Q, Wang Y, Gao X, Ma Z, Song Z. L-arginine reduces cell proliferation and ornithine decarboxylase activity in patients with colorectal adenoma and adenocarcinoma. Clin Cancer Res 2007;13: 7407-7412
13. Key TJ, Appleby PN, Spencer EA, Travis RC, Allen NE, Thorogood M, Mann JI. Cancer incidence in British vegetarians. Br J Cancer 2009;101:192-197
14. Gerner EW, Meyskens FL, Jr. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 2004;4: 781-792 (Pubitemid 39331150)
15. Singh R, Pervin S, Karimi A, Cederbaum S, Chaudhuri G. Arginase activity in human breast cancer cell lines: N(omega)-hydroxy- L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. Cancer Res 2000;60: 3305-3312 (Pubitemid 30407931)
16. Singh R, Pervin S, Wu G, Chaudhuri G. Activation of caspase-3 activity and apoptosis in MDA-MB-468 cells by N(omega)-hydroxy-L-arginine, an inhibitor of arginase, is not solely dependent on reduction in intracellular polyamines. Carcinogenesis 2001;22:1863-1869.
17. Meyskens FL, Jr., McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, Albers CG, Ahnen DJ, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Philadelphia) 2008;1:32-38
18. Babbar N, Gerner EW, Casero RA, Jr. Induction of spermidine/spermine N1- acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells. Biochem J 2006; 394:317-324
19. Brosnan ME, Brosnan JT. Hepatic glutamate metabolism: a tale of 2 hepatocytes. Am J Clin Nutr 2009;90: 857S-861S.
20. Grillo MA, Colombatto S. Arginine revisited: minireview article. Amino Acids 2004;26:345-351
21. Phang JM, Donald SP, Pandhare J, Liu Y. The metabolism of proline, a stress substrate, modulates carcinogenic pathways. Amino Acids 2008;35:681-690
22. Lyons SA, Chung WJ, Weaver AK, Ogunrinu T, Sontheimer H. Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res 2007;67: 9463-9471 (Pubitemid 47535936)
23. Pollock PM, Cohen-Solal K, Sood R, Namkoong J, Martino JJ, Koganti A, Zhu H, Robbins C, Makalowska I, Shin SS, Marin Y, Roberts KG, et al. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet 2003;34:108-112
24. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 2005;5: 641-654
25. Rodriguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 2008;222:180-191
26. Morris SM, Jr. Recent advances in arginine metabolism: roles and regulation of the arginases. Br J Pharmacol 2009;157:922-930
27. Wolf C, Bruss M, Hanisch B, Gothert M, von Kugelgen I, Molderings GJ. Molecular basis for the antiproliferative effect of agmatine in tumor cells of colonic, hepatic, and neuronal origin. Mol Pharmacol 2007; 71:276-283
28. Husson A, Brasse-Lagnel C, Fairand A, Renouf S, Lavoinne A. Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle. Eur J Biochem 2003; 270:1887-1899
29. Luiking YC, Hallemeesch MM, van de Poll MC, Dejong CH, de Jonge WJ, Lamers WH, Deutz NE. Reduced citrulline availability by OTC deficiency in mice is related to reduced nitric oxide production. Am J Physiol Endocrinol Metab 2008;295: E1315-E1322.
30. Kurz S, Harrison DG. Insulin and the arginine paradox. J Clin Invest 1997;99: 369-370
31. Xie L, Gross SS. Argininosuccinate synthetase overexpression in vascular smooth muscle cells potentiates immunostimulant-induced NO production. J Biol Chem 1997;272:16624-16630 (Pubitemid 27276494)
32. Goodwin BL, Solomonson LP, Eichler DC. Argininosuccinate synthase expression is required to maintain nitric oxide production and cell viability in aortic endothelial cells. J Biol Chem 2004;279: 18353-18360 (Pubitemid 38623250)
33. Closs EI, Simon A, Vekony N, Rotmann A. Plasma membrane transporters for arginine. J Nutr 2004;134:2752S-2759S; discussion 65S-67S.
34. Brasse-Lagnel C, Lavoinne A, Loeber D, Fairand A, Bole-Feysot C, Deniel N, Husson A. Glutamine and interleukin- 1beta interact at the level of Sp1 and nuclear factor-kappaB to regulate argininosuccinate synthetase gene expression. FEBS J 2007;274:5250-5262
35. Hao G, Xie L, Gross SS. Argininosuccinate synthetase is reversibly inactivated by S-nitrosylation in vitro and in vivo. J Biol Chem 2004;279:36192-36200
36. Satriano J. Agmatine: at the crossroads of the arginine pathways. Ann N Y Acad Sci 2003;1009:34-43.
37. Su TS, Bock HG, O'Brien WE, Beaudet AL. Cloning of cDNA for argininosuccinate synthetase mRNA and study of enzyme overproduction in a human cell line. J Biol Chem 1981;256:11826-11831
38. Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, Grimshaw MJ, Steele JP, Rudd RM, Balkwill FR, Fennell DA. In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res 2006;12:7126-7131
39. Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res 2002;62: 5443-5450
40. Dillon BJ, Prieto VG, Curley SA, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer 2004;100:826-833
41. Szlosarek PW, Grimshaw MJ, Wilbanks GD, Hagemann T, Wilson JL, Burke F, Stamp G, Balkwill FR. Aberrant regulation of argininosuccinate synthetase by TNFalpha in human epithelial ovarian cancer. Int J Cancer 2007;121:6-11. (Pubitemid 46753846)
42. Yoon CY, Shim YJ, Kim EH, Lee JH, Won NH, Kim JH, Park IS, Yoon DK, Min BH. Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. Int J Cancer 2007;120: 897-905.
43. Kim RH, Coates JM, Bowles TL, McNerney GP, Sutcliffe J, Jung JU, Gandour-Edwards R, Chuang FY, Bold RJ, Kung HJ. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res 2009;69: 700-708
44. Nicholson LJ, Smith PR, Hiller L, Szlosarek PW, Kimberley C, Sehouli J, Koensgen D, Mustea A, Schmid P, Crook T. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer 2009;125:1454-1463
45. Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, Savaraj N. Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des 2008;14: 1049-1057 (Pubitemid 351982554)
46. Su Y, Block ER. Hypoxia inhibits L-arginine synthesis from L-citrulline in porcine pulmonary artery endothelial cells. Am J Physiol 1995;269:L581-L587. (Pubitemid 3005941)
47. Karlberg T, Collins R, van den Berg S, Flores A, Hammarstrom M, Hogbom M, Holmberg Schiavone L, Uppenberg J. Structure of human argininosuccinate synthetase. Acta Crystallogr D Biol Crystallogr 2008;64:279-286
48. Fontenelle LJ, Henderson JF. Sources of nitrogen as rate-limiting factors for purine biosynthesis de novo in Ehrlich ascites tumor cells. Biochim Biophys Acta 1969; 177:88-93.
49. Krummrei U, Baulieu EE, Chambraud B. The FKBP-associated protein FAP48 is an antiproliferative molecule and a player in T cell activation that increases IL2 synthesis. Proc Natl Acad Sci USA 2003;100:2444-2449
50. Lagarde SM, Ver Loren van Themaat PE, Moerland PD, Gilhuijs-Pederson LA, Ten Kate FJ, Reitsma PH, van Kampen AH, Zwinderman AH, Baas F, van Lanschot JJ. Analysis of gene expression identifies differentially expressed genes and pathways associated with lymphatic dissemination in patients with adenocarcinoma of the esophagus. Ann Surg Oncol 2008;15: 3459-3470
51. Helleman J, Jansen MP, Span PN, van Staveren IL, Massuger LF, Meijer-van Gelder ME, Sweep FC, Ewing PC, van der Burg ME, Stoter G, Nooter K, Berns EM. Molecular profiling of platinum resistant ovarian cancer. Int J Cancer 2006;118: 1963-1971
52. Thompson CB. Metabolic enzymes as oncogenes or tumor suppressors. N Engl J Med 2009;360:813-815
53. Bode BP, Souba WW. Modulation of cellular proliferation alters glutamine transport and metabolism in human hepatoma cells. Ann Surg 1994;220:411-22; discussion 22-24
54. Vissers YL, Dejong CH, Luiking YC, Fearon KC, von Meyenfeldt MF, Deutz NE. Plasma arginine concentrations are reduced in cancer patients: evidence for arginine deficiency? Am J Clin Nutr 2005; 81:1142-1146
55. Wheatley DN. Controlling cancer by restricting arginine availability-arginine-catabolizing enzymes as anticancer agents. Anticancer Drugs 2004;15:825-833
56. Richards NG, Kilberg MS. Asparagine Synthetase Chemotherapy. Annu Rev Biochem 2006;75:629-654
57. Feun L, Savaraj N. Pegylated arginine deiminase: a novel anticancer enzyme agent. Expert Opin Investig Drugs 2006;15: 815-822
58. Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A, Beneduce G, De Rosa V, Izzo F, Melucci MT, Ensor CM, Prestayko AW, et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 2005;23: 7660-7668
59. Izzo F, Marra P, Beneduce G, Castello G, Vallone P, De Rosa V, Cremona F, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA, Ng C, et al. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 2004;22:1815-1822
60. Chen L, Chen P, Chao Y, Sheen I, Yang T, Wang T, Chen S, Lu S, Wang J, Liao L. A randomized phase II study of pegylated arginine deiminase (ADI-PEG 20) in advanced hepatocellular carcinoma (HCC) in Taiwan. ASCO GI Cancers Symp 2009; abstr 255.
61. Ott PA, Carvajal RD, Pandit-Taskar N, Jungbluth AA, Hoffman E, Venhaus R, Pan L, Old L, Pavlick AC, Wolchok JD. Phase I/II study of arginine deiminase (ADI-PEG 20) in patients with advanced malignant melanoma. J Clin Oncol 2009;27: 15s.
62. Bowles TL, Kim R, Galante J, Parsons CM, Virudachalam S, Kung HJ, Bold RJ. Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. Int J Cancer 2008;123:1950-1955
63. Cheng PN, Lam TL, Lam WM, Tsui SM, Cheng AW, Lo WH, Leung YC. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res 2007;67:309-317
64. Wang M, Basu A, Palm T, Hua J, Youngster S, Hwang L, Liu HC, Li X, Peng P, Zhang Y, Zhao H, Zhang Z, et al. Engineering an arginine catabolizing bioconjugate: Biochemical and pharmacological characterization of PEGylated derivatives of arginine deiminase from Mycoplasma arthritidis. Bioconjug Chem 2006;17:1447-1459
65. van de Poll MC, Hanssen SJ, Berbee M, Deutz NE, Monbaliu D, Buurman WA, Dejong CH. Elevated plasma arginase-1 does not affect plasma arginine in patients undergoing liver resection. Clin Sci (Lond) 2008;114:231-241 (Pubitemid 351293998)
66. Bubley GJ, Xu J, Kupiec N, Sanders D, Foss F, O'Brien M, Emi Y, Teicher BA, Patierno SR. Effect of DNA conformation on cisplatin adduct formation. Biochem Pharmacol 1996;51:717-721 (Pubitemid 26080145)
67. Tang CH, Grimm EA. Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. J Biol Chem 2004;279:288-298
68. Morris JG. Nutritional and metabolic responses to arginine deficiency in carnivores. J Nutr 1985;115:524-531 (Pubitemid 15083811)
69. Coman D, Yaplito-Lee J, Boneh A. New indications and controversies in arginine therapy. Clin Nutr 2008;27:489-496
70. Xia Y, Zweier JL. Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. Proc Natl Acad Sci USA 1997;94:6954-6958 (Pubitemid 27281972)
71. Seo JH, Sung HJ, Choi CW, Kim BS, Shin SW, Kim YH, Min BH, Kim JS. Extrinsic nitric oxide donor partially reverses arginine deiminase induced cell growth inhibition through NFkappaB and Bcl-X L. Invest New Drugs 2008;26:277-282
72. Starbuck WC, Busch H. Kinetics of incorporation of L-arginine-U-C14 into nuclear proteins of tumors and other tissues in vitro. Cancer Res 1960;20:891-896
73. Park IS, Kang SW, Shin YJ, Chae KY, Park MO, Kim MY, Wheatley DN, Min BH. Arginine deiminase: a potential inhibitor of angiogenesis and tumour growth. Br J Cancer 2003;89:907-914
74. Gong H, Pottgen C, Stuben G, Havers W, Stuschke M, Schweigerer L. Arginine deiminase and other antiangiogenic agents inhibit unfavorable neuroblastoma growth: potentiation by irradiation. Int J Cancer 2003;106:723-728 (Pubitemid 36993396)
75. Gong H, Zolzer F, von Recklinghausen G, Rossler J, Breit S, Havers W, Fotsis T, Schweigerer L. Arginine deiminase inhibits cell proliferation by arresting cell cycle and inducing apoptosis. Biochem Biophys Res Commun 1999;261:10-14
76. Onodera J, Ohsumi Y. Autophagy is required for maintenance of amino acid levels and protein synthesis under nitrogen starvation. J Biol Chem 2005;280: 31582-31586
77. Shen LJ, Lin WC, Beloussow K, Shen WC. Resistance to the anti-proliferative activity of recombinant arginine deiminase in cell culture correlates with the endogenous enzyme, argininosuccinate synthetase. Cancer Lett 2003;191:165-170 (Pubitemid 36255601)
78. Tsai WB, Aiba I, Lee SY, Feun L, Savaraj N, Kuo MT. Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/ HIF-1alpha/Sp4. Mol Cancer Ther 2009;8: 3223-3233
79. Fernandez J, Yaman I, Mishra R, Merrick WC, Snider MD, Lamers WH, Hatzoglou M. Internal ribosome entry site-mediated translation of a mammalian mRNA is regulated by amino acid availability. J Biol Chem 2001;276:12285-12291
80. Espat NJ, Copeland EM, Souba WW. Accelerated hepatic arginine transport in the tumor-bearing rat. Ann Surg Oncol 1994;1:147-156
81. Nussler AK, Billiar TR, Liu ZZ, Morris SM, Jr. Coinduction of nitric oxide synthase and argininosuccinate synthetase in a murine macrophage cell line. Implications for regulation of nitric oxide production. J Biol Chem 1994;269:1257-1261
82. White MF, Christensen HN. The two-way flux of cationic amino acids across the plasma membrane of mammalian cells is largely explained by a single transport system. J Biol Chem 1982;257:10069-10080
83. Davidson JS, Baumgarten IM, Harley EH. Metabolic cooperation between argininosuccinate synthetase and argininosuccinate lyase deficient human fibroblasts. Exp Cell Res 1984;150: 367-378 (Pubitemid 14192478)
84. Rho JH, Qin S, Wang JY, Roehrl MH. Proteomic expression analysis of surgical human colorectal cancer tissues: up-regulation of PSB7, PRDX1, and SRP9 and hypoxic adaptation in cancer. J Proteome Res 2008;7:2959-2972
85. Murakami A, Kawabata K, Koshiba T, Gao G, Nakamura Y, Koshimizu K, Ohigashi H. Nitric oxide synthase is induced in tumor promoter-sensitive, but not tumor promoter-resistant, JB6 mouse epidermal cells cocultured with interferon-gamma-stimulated RAW 264.7 cells: the role of tumor necrosis factor-alpha. Cancer Res 2000;60:6326-6331
86. Inoue Y, Bode BP, Copeland EM, Souba WW. Enhanced hepatic amino acid transport in tumor-bearing rats is partially blocked by antibody to tumor necrosis factor. Cancer Res 1995;55:3525-3530